Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab Combinations in Advanced Melanoma
NCT03484923Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2018
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 10
01
Overview
A Phase 2 trial of spartalizumab in melanoma, sponsored by Novartis. Started Sep 2018; status: completed.
02
Drugs
spartalizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03484923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03484923.